Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Clearside discontinues combo therapy for retinal vein occlusion

Clearside Biomedical Inc. (NASDAQ:CLSD) discontinued development of Xipere (formerly CLS-TA) plus Eylea aflibercept to treat macular edema following retinal vein occlusion (RVO)

Read the full 220 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE